Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › lebrikizumab

lebrikizumab

2 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials of lebrikizumab

14 trials tracked of lebrikizumab: 10 in phase 3 or 4 and 9 with published results. The most-cited published study has 151 citations.

14Trials tracked
10Phase 3 & 4
0Recruiting
9With published results
Phase distribution
Phase 3 10 Phase 2 2 Phase 1 2
  1. Phase 3 Safety and Efficacy of Lebrikizumab (LY3650150) in Combination With Topical Corticosteroid in Moderate-to-Severe Atopic Dermatitis. Completed · 151 cited
  2. Phase 3 Study to Assess the Safety and Efficacy of Lebrikizumab (LY3650150) in Adolescent Participants With Moderate-to-Severe Atopic Dermatitis Completed · 46 cited
  3. Phase 3 Long-term Safety and Efficacy Study of Lebrikizumab (LY3650150) in Participants With Moderate-to-Severe Atopic Dermatitis (ADjoin) Completed · 13 cited
  4. Phase 3 Evaluation of the Efficacy and Safety of Lebrikizumab (LY3650150) in Moderate to Severe Atopic Dermatitis Completed · 12 cited
  5. Phase 3 Evaluation of the Efficacy and Safety of Lebrikizumab (LY3650150) in Moderate to Severe Atopic Dermatitis (ADvocate1) Completed · 12 cited
  6. Phase 3 A Study of (LY3650150) Lebrikizumab to Assess the Safety and Efficacy of Adult and Adolescent Participants With Moderate-to-Severe Atopic Dermatitis and Skin of Color Completed · 8 cited
Show 8 more trials
  1. Phase 3 A Study of Lebrikizumab (LY3650150) in Combination With Topical Corticosteroids in Japanese Participants With Moderate-to-Severe Atopic Dermatitis Completed · 8 cited
  2. Phase 3 A Study of Lebrikizumab (LY3650150) in Adult and Adolescent Participants With Moderate-to-Severe Atopic Dermatitis Previously Treated With Dupilumab Completed · 6 cited
  3. Phase 3 A Study of Lebrikizumab (LY3650150) on Vaccine Response in Adults With Atopic Dermatitis (ADopt-VA) Completed · 3 cited
  4. Phase 3 A Study of Lebrikizumab in Combination With Topical Corticosteroids in Patients With Atopic Dermatitis (AD) That Are Not Adequately Controlled With or Are Non-eligible for Cyclosporine Completed
  5. Phase 2 A Study of Lebrikizumab (LY3650150) in Participants With Moderate-to-Severe Atopic Dermatitis Completed
  6. Phase 2 A Study of Lebrikizumab in Participants With Idiopathic Pulmonary Fibrosis (IPF) Completed
  7. Phase 1 A Study of Lebrikizumab (LY3650150) Administered by Two Different Devices in Healthy Participants Completed
  8. Phase 1 A Study to Investigate the Safety and Pharmacokinetics of Lebrikizumab in Healthy Chinese Participants Completed

Showing the 14 most-cited and recently-updated of 14 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Dupilumab, Lebrikizumab, Tralokinumab All Beat Placebo in Adolescent Eczema, No Clear Winner
Dermatology Sys. Review
Dupilumab, Lebrikizumab, Tralokinumab All Beat Placebo in Adolescent Eczema, No Clear Winner New Treatments Show Promise for Severe Adolescent Atopic Dermatitis
This network meta-analysis of 642 adolescents aged 12 to 17 with moderate-to-severe atopic dermatitis found that dupilumab, lebrikizumab, an…
New data shows that dupilumab, lebrikizumab, and tralokinumab may help teens with moderate to severe atopic dermatitis.
Oct 1, 2026
Secondary analysis of Phase 3 trials shows lebrikizumab improves absolute EASI response in moderate-to-severe atopic dermatitis
Dermatology RCT
Secondary analysis of Phase 3 trials shows lebrikizumab improves absolute EASI response in moderate-to-severe atopic dermatitis New analysis shows lebrikizumab helps clear skin faster than placebo for atopic dermatitis
This secondary analysis of two Phase 3 trials evaluated lebrikizumab 250 mg Q2W versus placebo in adults and adolescents with moderate-to-se…
A look at two major trials found lebrikizumab led to significantly better skin clearing than placebo in adults and adolescents with moderate…
May 21, 2026